Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes (Q44460021)
Jump to navigation
Jump to search
scientific article published on 7 January 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes |
scientific article published on 7 January 2014 |
Statements
1 reference
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes (English)
1 reference
Julio Rosenstock
1 reference
Robert R Henry
1 reference
Douglas Logan
1 reference
Thomas Alessi
1 reference
Kenneth Luskey
1 reference
Michelle A Baron
1 reference
7 January 2014
1 reference
1 reference
Identifiers
1 reference